NEW YORK (GenomeWeb News) - AstraZeneca has signed a three-year agreement for BioWisdom’s Safety Intelligence Program, an initiative to develop an “intelligence system” to analyze drug safety and toxicity data for use in drug discovery and development.
 
BioWisdom said AstraZeneca is its first partner for the program, and as such takes a place on the firm’s SIP advisory board. 
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.